Lineage Cell Therapeutics Inc
TASE:LCTX
Intrinsic Value
The intrinsic value of one LCTX stock under the Base Case scenario is 990.26 ILS. Compared to the current market price of 361.6 ILS, Lineage Cell Therapeutics Inc is Undervalued by 63%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Lineage Cell Therapeutics Inc
Fundamental Analysis

Revenue & Expenses Breakdown
Lineage Cell Therapeutics Inc
Balance Sheet Decomposition
Lineage Cell Therapeutics Inc
Current Assets | 50m |
Cash & Short-Term Investments | 47.9m |
Receivables | 213k |
Other Current Assets | 1.9m |
Non-Current Assets | 61.8m |
PP&E | 4.1m |
Intangibles | 57.2m |
Other Non-Current Assets | 504k |
Free Cash Flow Analysis
Lineage Cell Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Lineage Cell Therapeutics Inc
Revenue
|
9.6m
USD
|
Cost of Revenue
|
-272k
USD
|
Gross Profit
|
9.3m
USD
|
Operating Expenses
|
-30.6m
USD
|
Operating Income
|
-21.3m
USD
|
Other Expenses
|
5.1m
USD
|
Net Income
|
-16.2m
USD
|
LCTX Profitability Score
Profitability Due Diligence
Lineage Cell Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Lineage Cell Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
LCTX Solvency Score
Solvency Due Diligence
Lineage Cell Therapeutics Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Lineage Cell Therapeutics Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LCTX Price Targets Summary
Lineage Cell Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for LCTX is 1 300.97 ILS with a low forecast of 493.36 ILS and a high forecast of 3 077.37 ILS.
Dividends
Current shareholder yield for LCTX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one LCTX stock under the Base Case scenario is 990.26 ILS.
Compared to the current market price of 361.6 ILS, Lineage Cell Therapeutics Inc is Undervalued by 63%.